Effects of stannous fluoride dentifrice on gingival health and oxidative stress markers: a prospective clinical trial.

Autor: Ramji N; The Procter & Gamble Company, Mason Business and Innovation Center, 8700 Mason-Montgomery Road, Mason, OH, 45040, USA. ramji.n@pg.com., Xie S; The Procter & Gamble Company, Mason Business and Innovation Center, 8700 Mason-Montgomery Road, Mason, OH, 45040, USA., Bunger A; The Procter & Gamble Company, Mason Business and Innovation Center, 8700 Mason-Montgomery Road, Mason, OH, 45040, USA., Trenner R; The Procter & Gamble Company, Mason Business and Innovation Center, 8700 Mason-Montgomery Road, Mason, OH, 45040, USA., Ye H; The Procter & Gamble Company, Mason Business and Innovation Center, 8700 Mason-Montgomery Road, Mason, OH, 45040, USA., Farmer T; The Procter & Gamble Company, Mason Business and Innovation Center, 8700 Mason-Montgomery Road, Mason, OH, 45040, USA., Reichling T; The Procter & Gamble Company, Mason Business and Innovation Center, 8700 Mason-Montgomery Road, Mason, OH, 45040, USA., Ashe J; The Procter & Gamble Company, Mason Business and Innovation Center, 8700 Mason-Montgomery Road, Mason, OH, 45040, USA., Milleman K; Salus Research Inc, 1220 Medical Park Drive, Building 4, Ft. Wayne, Fort Wayne, IN, 46825, USA., Milleman J; Salus Research Inc, 1220 Medical Park Drive, Building 4, Ft. Wayne, Fort Wayne, IN, 46825, USA., Klukowska M; The Procter & Gamble Company, Mason Business and Innovation Center, 8700 Mason-Montgomery Road, Mason, OH, 45040, USA.
Jazyk: angličtina
Zdroj: BMC oral health [BMC Oral Health] 2024 Aug 30; Vol. 24 (1), pp. 1019. Date of Electronic Publication: 2024 Aug 30.
DOI: 10.1186/s12903-024-04785-7
Abstrakt: Background: Periodontal disease results in oral dysbiosis, increasing plaque virulence and oxidative stress. Stannous fluoride (SnF 2 ) binds lipopolysaccharides to reduce plaque virulence. This study prospectively assessed SnF 2 effects on oxidative stress in adults with gingivitis.
Methods: This was a 2-month, single-center, single-treatment clinical trial. Twenty "disease" (> 20 bleeding sites with ≥ 3 pockets 3 mm-4 mm deep) and 20 "healthy" (≤ 3 bleeding sites with pockets ≤ 2 mm deep) adults were enrolled. All participants were instructed to use SnF 2 dentifrice twice daily for 2 months. An oral examination, Modified Gingival Index (MGI) examination and Gingival Bleeding Index (GBI) examination were conducted at baseline, 1 month and 2 months. Gingival crevicular fluid (GCF), saliva, oral lavage and supragingival plaque were collected at each visit to evaluate: Endotoxins, Protein Carbonyls, L-lactate dehydrogenase (LDH), Ferric reducing antioxidant power (FRAP), Oxidized low density lipoproteins (oxi-LDL), IL-6 and C-reactive protein (CRP). A subset-analysis examined participants considered at higher risk of cardiovascular disease. Change-from-baseline analyses within each group were of primary interest.
Results: The disease group showed statistically significant reductions in GBI at Month 1 (67%) and Month 2 (85%) and in MGI at Month 1 (36%) and Month 2 (51%) versus baseline (p < 0.001). At baseline, the disease group showed greater LDH in GCF and oxi-LDL levels in saliva versus the healthy group (p ≤ 0.01). Total antioxidant capacity (FRAP) in saliva increased versus baseline for the disease group at Months 1 and 2 (p < 0.05), and levels for the disease group were greater than the healthy group at both timepoints (p < 0.05). SnF 2 treatment reduced endotoxins (lavage) for both disease and healthy groups at Month 2 (p ≤ 0.021) versus baseline. There was a reduction in oxidative stress markers, namely protein carbonyl in saliva, at Months 1 and 2 (p < 0.001) for both groups and a reduction in cytokine IL-6 (lavage) in the disease group at Month 2 (p = 0.005). A subset analysis of participants at higher coronary disease risk showed reductions in endotoxins in lavage, oxi-LDL, and CRP in saliva at Month 2 (p ≤ 0.04).
Conclusion: SnF 2 dentifrice use reversed gingival inflammation, suppressed endotoxins and reduced some harmful oxidant products in saliva and gingiva.
Clinical Trial Registration: Clinicaltrials.gov NCT05326373, registered on 13/04/2022.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: